471 patents
Page 18 of 24
Utility
Combination of an ANTI-PD-L1 Antibody and IDO1 Inhibitor for the Treatment of Cancer
6 Jan 21
The present invention relates to combination therapies useful for the treatment of cancer.
Brian A. SHERER, Claude GIMMI, Jacques MOISAN
Filed: 18 Dec 18
Utility
Combination of a Cyclin Dependent Kinase Inhibitor and a Bet- Bromodomain Inhibitor
30 Dec 20
This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor that inhibits CDK4 and/or CDK6, and a bromodomain and extra-terminal domain (BET) family inhibitor, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
Lars Anders, Danan Li
Filed: 21 Feb 19
Utility
Immunogenic Compositions for Use In Pneumococcal Vaccines
30 Dec 20
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates.
Fiona Laichu Lin, Viliam Pavliak, Michael William Pride, Shite Sebastian
Filed: 23 Aug 20
Utility
Neisseria Meningitidis Compositions and Methods Thereof
30 Dec 20
In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick
Filed: 16 Sep 20
Utility
Compounds for the Treatment of Braf-associated Diseases and Disorders
30 Dec 20
Patrick Michael BARBOUR, Katie Keaton BROWN, Adam Wade COOK, Erik James HICKEN, Dean Russell KAHN, Ellen Ruth LAIRD, Andrew Terrance METCALF, David Austin MORENO, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Brett Joseph PRIGARO, Li REN, Eugene TARLTON
Filed: 23 Jun 20
Utility
PYRAZOLO[1,5-A]PYRAZIN-4-YL Derivatives
23 Dec 20
Matthew Frank BROWN, Alpay DERMENCI, Andrew FENSOME, Brian Stephen GERSTENBERGER, Matthew Merrill HAYWARD, Dafydd Rhys OWEN, Stephen Wayne WRIGHT, Li Huang XING, Xiaojing YANG
Filed: 7 Sep 20
Utility
Benzisoxazole Sulfonamide Derivatives
23 Dec 20
Ylva Elisabet Bergman Bozikis, Oleg Brodsky, Michelle Ang Camerino, Samantha Elizabeth Greasley, Robert Louis Hoffman, Robert Arnold Kumpf, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple, Scott Channing Sutton
Filed: 15 Jun 20
Utility
SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
23 Dec 20
James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Li REN
Filed: 17 Jan 19
Utility
CDK2/4/6 Inhibitors
16 Dec 20
Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
Filed: 26 Aug 20
Utility
MUTEINS OF CLOTTING FACTOR Vlll
16 Dec 20
The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
Filed: 23 Feb 20
Utility
CorrectedSubstituted PYRAZOLO[1,5-A]PYRIDINE Compounds As Ret Kinase Inhibitors
9 Dec 20
Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, James COLLIER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. McFADDIN, Megan L. McKENNEY, Oren T. McNULTY, Andrew T. METCALF, David A. MORENO, Ginelle A. RAMANN, Tony P. TANG, Li REN, Shane M. WALLS
Filed: 22 Sep 19
Utility
Substituted 3-AZABICYCLO[3.1.0]HEXANES As Ketohexokinase Inhibitors
2 Dec 20
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
Filed: 20 Aug 20
Utility
Apixaban Formulations
2 Dec 20
Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
Jatin Patel, Charles Frost, Jingpin Jia, Chandra Vemavarapu
Filed: 13 May 20
Utility
Bicyclic-Fused Heteroaryl or Aryl Compounds
2 Dec 20
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
Filed: 17 Aug 20
Utility
Site Specific HER2 Antibody Drug Conjugates
2 Dec 20
The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
Dangshe MA, Frank LOGANZO, Jr., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
Filed: 2 Jun 20
Utility
Methods and Combination Therapy to Treat Cancer
25 Nov 20
This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that consist essentially of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.
Patrice A. LEE, David CHANTRY, Shannon L. WINSKI
Filed: 9 Jan 18
Utility
Immunogenic Compositions and Uses Thereof
25 Nov 20
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant.
Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
Filed: 3 Aug 20
Utility
PD-1/PD-L1 Inhibitors for the Treatment of Cancer
18 Nov 20
The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
Jean-Marie Cuillerot, Anja von Heydebreck, Guojun Yuan
Filed: 4 Aug 20
Utility
Cyclin Dependent Kinase Inhibitors
11 Nov 20
Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
Filed: 28 Jul 20
Utility
Crystalline 2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol Salt of 4-(4-(1-Isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypryridin-2-YL)benzoic acid
11 Nov 20
The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.
Dilinie Fernando, Shawn Marie LaCasse, Kristin Elizabeth Price Wiglesworth
Filed: 13 Nov 18